Quintrio
Home

OPHTHALMIC GOODS

RxSight, Inc. Common Stock

RXST

RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.

Last trade $4.92
Day change -$0.38 (-7.17%)
Day range $4.90 – $5.92
Volume 430,206
Market cap $222M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$222.22M
Price / earnings
—
Price / book
0.87×
Price / sales
1.82×
EV / sales
1.28×
EV / EBITDA
-2.69×

Profitability

Earnings per share
-$1.28
Return on assets
-15.72%
Return on equity
-20.99%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
4.2×
Quick ratio
3.67×
Cash ratio
0.89×

Cash flow

Price / cash flow
9.39×
Price / free cash flow
11.92×
Free cash flow
$18.65M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for RXST, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$24.59M$33.74M$30.89M$32.61M$30.34M$33.64M$37.9M$40.21M
Cost of revenue$6.49M$7.86M$7.4M$7.35M$6.11M$8.45M$9.57M$11.43M
Gross profit$18.1M$25.89M$23.5M$25.26M$24.23M$25.19M$28.33M$28.79M
Selling, general and administrative$27.4M$30.42M$31.86M$27.7M$27.35M$28.98M$28.64M$28.21M
Research and development$9.21M$9.24M$9.47M$8.91M$9.06M$10.22M$10.37M$9.21M
Total operating expenses$36.62M$39.66M$41.33M$36.6M$36.41M$39.19M$39M$37.42M
Operating income-$18.52M-$13.77M-$17.83M-$11.34M-$12.18M-$14M-$10.67M-$8.63M
Interest expense-$3K-$3K-$3K-$5K-$4K-$5K-$6K-$5K
Income before taxes-$16.2M-$12.01M-$15.88M-$9.15M-$9.81M-$11.75M-$8.17M-$5.93M
Income taxes$28K$88K$6K$5K$10K$32K$18K$12K
Net income-$16.22M-$12.1M-$15.88M-$9.15M-$9.82M-$11.79M-$8.19M-$5.94M
Net income attributable to common shareholders-$16.27M-$12.1M-$16M-$9.15M-$9.64M-$11.79M-$8.34M-$5.94M
EBITDA-$17.59M-$12.77M-$17M-$10.49M-$11.32M-$13.22M-$9.9M-$8.11M
Basic earnings per share-$0.39-$0.29-$0.38-$0.22-$0.24-$0.29-$0.20-$0.15
Diluted earnings per share-$0.39-$0.29-$0.38-$0.22-$0.24-$0.29-$0.20-$0.15

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

RxSight, Inc. (RXST) Reports Q3 Loss, Lags Revenue Estimates

RxSight (RXST) beat EPS expectations with a loss of $0.21 per share versus consensus estimate of $0.29, representing a 27.59% earnings surprise. However, the company missed revenue estimates, posting $24.59 million versus the expected amount, down from $30.34 million year-over-year. The stock has underperformed significantly, down 53.9% year-to-date. RxSight holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.

GlobeNewswire Inc.

K2 Vision Has Been Recognized as the Highest-Volume Light Adjustable Lens practice in the world

K2 Vision, a Pacific Northwest and Arizona-based vision correction practice, has completed 5,000 Light Adjustable Lens (LAL) procedures and been recognized by RxSight as the world's highest-volume LAL practice. The LAL is the first lens implant that can be adjusted after placement through noninvasive light treatments, allowing for customized vision correction based on patient needs.

GlobeNewswire Inc.

RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer

RxSight, Inc. announced preliminary 2025 full-year revenue of $134.5 million, exceeding guidance, driven by 109,615 Light Adjustable Lens procedures (12% increase YoY) and expansion of its installed base to 1,134 Light Delivery Devices. The company also appointed Mark Wilterding as Chief Financial Officer, bringing 25+ years of medtech financial leadership experience from Edwards Lifesciences.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Sep 21, 20069-for-1forward split